WALTHAM, Massachusetts — Thermo Fisher Scientific Inc., the world leader in serving science, announced an expansion of its bioprocessing capabilities across Asia with the opening of a new Bioprocess Design Center in Hyderabad, India, and major enhancements to its centers in Incheon, Korea, and Singapore. The investment deepens the company’s support for Asia’s fast-growing biopharmaceutical sector and strengthens a regional network aimed at improving speed, efficiency and sustainability in biomanufacturing.
Asia has rapidly emerged as a global hub for biopharmaceutical innovation, driven by increasing demand for biologics, vaccines and cell and gene therapies. Thermo Fisher’s expanded footprint provides customers across the region with localized expertise, advanced technologies and tailored support to accelerate development and manufacturing of life-changing therapies.
“Asia continues to play an increasingly important role in advancing innovation across the global biopharma industry,” said Daniella Cramp, senior vice president and president of BioProduction at Thermo Fisher Scientific. “By expanding our network in Korea, Singapore and India, we’re bringing world-class infrastructure and expertise closer to our customers, helping them deliver high-quality biologics faster, more cost-effectively and more sustainably.”
The company’s tri-hub network now links Bioprocess Design Centers in Incheon, Hyderabad and Singapore, creating a streamlined platform for collaboration, process development and technical training.
In Incheon, the newly expanded center offers advanced materials, technologies and enhanced laboratory capabilities to support deeper customer collaboration. The new Hyderabad center, located in Genome Valley and developed in partnership with the Government of Telangana, provides collaborative workspaces for process design, simulation and optimization. It gives customers access to the latest single-use and hybrid systems to support India’s growing biomanufacturing ecosystem. In Singapore, the expanded facility offers bench-to-pilot scale bioprocessing, hands-on training and direct technical support to help scale early-stage processes and advance flexible, sustainable manufacturing.
These centers are designed to give biopharma innovators direct access to Thermo Fisher’s technologies, training and technical expertise, improving agility and reducing time to market for biologics.
Thermo Fisher supports biopharmaceutical development from early research through commercial production with technologies spanning next-generation sequencing, mass spectrometry, and advanced bioprocessing systems. The company’s offerings across life sciences, diagnostics, analytical instruments and pharma services enable customers throughout the biopharma value chain.
“Through advanced manufacturing, strategic partnerships and targeted regional investments, we are redefining what is possible in biologics production,” said Tony Acciarito, president of Asia Pacific and Middle East, Africa at Thermo Fisher Scientific. “We are proud to contribute to the transformation of Asia’s biopharma ecosystem and help our customers bring life-changing therapies to patients across Asia and beyond.”
